This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Sep 2011

AstraZeneca Wins Japanese Approval for Faslodex

AstraZeneca has received regulatory approval for its breast cancer drug Faslodex (fulvestrant) 500mg in Japan.

Global pharmaceutical and biologics company AstraZeneca has received Japanese regulatory approval for Faslodex (fulvestrant) 500mg, an oestrogen receptor antagonist for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer.

 

The company plans to introduce Faslodex 500mg in Japan by the end of 2011.

 

The results of a Phase III study led to the approval of Faslodex 500mg in Europe in March 2010 and the US in September 2010.

 

AstraZeneca Global Commercial Organisation executive vice-president Tony Zook said that metastatic breast cancer treatment primarily aims to prevent disease progression besides maintaining quality of life and Faslodex 500mg will provide women with be

Related News